A Study to Evaluate Comparative Bioavailability of BMS-986278 in Healthy Participants
Completed · Phase 1 · NCT06715683
Conditions: Healthy Volunteers
At a glance
- Research payments reported, 2025
- $151
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 48
About the trial
- Sponsor
- Bristol-Myers Squibb
- Tested
- BMS-986278 Batched method, Dose A (drug), BMS-986278 Batched method, Dose B (drug), BMS-986278 Continuous method (drug)
- Dates
- Started 2024-12-12; completion 2025-03-16
- Results posted
- Not yet
This is a trial to evaluate the comparative bioavailability of BMS-986278 to-be-marketed formulation compared to the phase 3 clinical trial formulation in healthy participants.
From ClinicalTrials.gov, last updated 2025-04-04. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $151 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Anaheim Clinical Trials $151
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.